Agilent Technologies and Veeda Lifesciences have announced a strategic collaboration aimed at strengthening regulatory-aligned analytical and bioanalytical workflows for biopharma development as GLP-1 and other advanced therapeutic modalities continue to progress across global pipelines. The partnership will combine Agilent’s analytical workflow development expertise with Veeda’s bioanalytical, clinical research and regulatory capabilities to support biopharma companies seeking inspection-ready analytical data throughout development and manufacturing stages. The companies said the initiative is designed to help sponsors manage increasing regulatory scrutiny and growing data expectations associated with next-generation therapies. The newly established Analytics Hub will operate from Veeda’s Bengaluru biopharma facility and focus on scalable analytical workflows for complex biologics and peptide-based therapies.
The collaboration includes the launch of a joint Center of Excellence at Veeda’s Bengaluru site, where the companies plan to develop and validate end-to-end analytical workflows for emerging therapies. The facility is intended to support analytical requirements linked to GLP-1 drugs and other complex biologics where throughput, sensitivity and data integrity remain essential for regulatory confidence and clinical progression. “As GLP-1 and other complex therapies move rapidly through development, the need for robust, regulatory-aligned analytics becomes increasingly critical,” said Nandakumar Kalathil. “Through our collaboration with Veeda, we aim to support biopharma organizations with workflow-driven analytical approaches that strengthen data quality, compliance, and confidence across the development lifecycle.”
Bharat Bhardwaj said the collaboration reflects Agilent’s commitment to supporting customers with scalable analytical systems and globally aligned development capabilities across the drug development lifecycle. He added that Asia Pacific continues to strengthen its position as a center for globally relevant biopharma research. Binoy Gardi stated that biopharma companies increasingly require inspection-ready analytical systems from the early stages of development and that the collaboration would help improve integrated analytical workflows supporting clinical and manufacturing programs. According to Sanjib Banerjee, the expanded service platform will support analytical characterization of peptides, monoclonal antibodies, antibody-drug conjugates and therapeutic proteins using Agilent’s mass spectrometry technologies alongside Veeda’s proteomics and impurity analysis capabilities.
The companies said the platform combines Agilent’s mass spectrometry systems with Veeda’s bioanalytical and clinical research infrastructure to provide sponsors with inspection-ready datasets across multiple therapeutic modalities. The Analytics Hub also reflects the companies’ broader effort to strengthen India’s advanced biopharma research infrastructure and reinforce the country’s role in globally aligned drug development services.
